Evaluation of protective effect of IL-22 and IL-12 on cutaneous leishmaniasis in BALB/c mice

Asian Pacific Journal of Tropical Medicine

Volumn 7, Issue 12, 2014, Pages 940-945

  Hezarjaribi, Hajar Ziaei ^a   Ghaffarifar, Fatemeh ^b   Dalimi, Abdolhossein ^b   Sharifi, Zohreh ^c  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

IL 12; IL 22; Leishmania major; Mice; Protection

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 22; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; LEISHMANIA MAJOR; LYMPHOCYTE CULTURE; MORTALITY; MOUSE; NONHUMAN; PLASMID; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; SKIN PROTECTION; SPLEEN; SURVIVAL RATE;

EID: 84918788481     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(14)60166-8     Document Type: Article

References (26)

1. Reed SG Leishmaniasis vaccination: targeting the source of infection. Exp Med 2001, 194(3):F7-F9.
2. WHO Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. WHO Technical Report No. 949. apps[Online] [Accessed 10 March 2013]. http://who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf.
3. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012, 7(5):e35671. 10.1371/journal.pone.0035671.
4. Wolff JA, Malone RW, Williams P, Ascadi G, Jani A, Felgner PL Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 pt 1):1465-1468.
5. Bhopale GM Development of a vaccine for toxoplasmosis: current status. Microb Infect 2003, 5:457-462.
6. Kofta W, Wedrychowicz H c-DNA vaccination against parasitic Infection: Advantages and disadvantages. Vet Parasitol 2001, 100:3-12.
7. Hoseinian Khosroshahi K, Ghaffarifar F, Sharifi Z, D'souza S, Dalimi A, Hassan Z, et al. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol Res 2012, 111:403-411.
8. Archambaud C, Sansoni A, mingueneau M, Devilard E, Delsol G, Malissen B, et al. STAT6 deletion converts the Th2 inflammatory pathology afflicting Lat (Y136F) mice into a lympho proliferative disorder involving Th1 and CD8 effector T cells. J Immunol 2009, 182(5):2680-2689.
9. Beraghella AM, Totaro R, Pellegrini P, Contasta I, Russo T, Carolei A, et al. Immunological study of IFN beta-1a-treated and untreated multiple sclerosis patients: clatifying IFN beta mechanisms and establishing specific dendritic cell immunotherapy. Neuroimmunomodulation 2005, 12(1):29-44.
10. Muller I, Titus R, Caldumbide I, Louis JA T cell responses in resistance and susceptibility to experimental infection with Leishmania major. Frontiers of infectious diseases "New strategies in parasitology 1989, 158-175. Churchill Livingston, London. M. Adam, K.E. Al (Eds.).
11. Louis JA, Muller I Experimental infection of mice with Leishmania major: Analysis of the role of T cells in resistance and susceptibility. Progress in immunology 1989, 971-978. Springer Verlag, Berlin. F.E.A. Melchers (Ed.).
12. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001, 167(7):3545-3549.
13. Conti P, Kempuraj D, Frydas S, Kandere K, Boucher W, Letourneau R, et al. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol Lett 2003, 88(3):171-174.
14. Igwa D, Sakai M, Savan R An unexpected discovery of two interferon gamma-like genes along with interleukin (IL) 22 and 26 from teleost: IL-22 and -26 genes have been described for the first time outside mammals. Mol Immunol 2006, 43(7):999-1009.
15. Dumoutier L, Van RE, Ameye G, Michaux L, Renauld JC IL-TIF/IL-22: genomic organization and mapping of the human and mouse gene. Genes Immun 2000, 1(8):488-494.
16. Npcddlrjoceal AR Crystal structure of recombinant human interleukin-22. Stucture 2002, 10:1051-1062.
17. Boniface K IL22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695-3702.
18. Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV, et al. IL22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009, 183:6639-6645.
19. Maira G, Pitta R, Romano A, Cabantous S, Sandrine H, Hammad A, et al. IL17 and IL22 are associated with protection against human Kala azar caused by Leishmania donovani. J Clin Invest 2009, 119:2379-2387.
20. Ziaee Hezarjarib H, Ghaffarifar F, Dalimi A, Sharifi Z The survey of the effect of cytokine IL22 on the ulcer originated from L. major in BALB/c mice. J Mazand Univ Med Sci 2012, 12:285-294.
21. Ghaffarifar F, Jorjani O, Sharifi Z, Dalimi A, Hassan Z, Tabatabaie F, et al. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS 2013, 121(4):290-298. 10.1111/j.1600-0463.2012.02968.x.
22. Farnandez-Botran R, Vetyickaz V Methods in cellular immunology 2001, CRF Press LNC, Portland. 2nd ed.
23. Tapia E, Perez-Jimenez E The combination of DNA vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003, 5(2):73-84.
24. Radaeva S, Sun R, Pan HN, Hong F, Gao B Interleukin 22(IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor hepatocytes via STAT3 activation. Hepatology 2004, 39(5):1332-1342.
25. Aujla SJ, Kolls JK IL-22: A critical mediator in mucosal host defense. J Mol Med 2009, 87:451-454.
26. Ziaee Hezarjaribi H, Ghaffarifar F, Dalimi A, Sharifi Z, Jorjani O Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice. Exp Parasitol 2013, 134:141-148.